Nilotinib

• UNSPSC Description:

  Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity.

• Target Antigen:

  Autophagy; Bcr-Abl

• Type:

  Reference compound

• Related Pathways:

  Autophagy;Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Nilotinib.html

• Purity:

  99.94

• Solubility:

  DMSO : 12.5 mg/mL (ultrasonic;warming;heat to 60°C)|H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  O=C(NC1=CC(C(F)(F)F)=CC(N2C=NC(C)=C2)=C1)C3=CC=C(C)C(NC4=NC=CC(C5=CC=CN=C5)=N4)=C3

• Molecular Weight:

  529.52

• References & Citations:

  [1]Weisberg E, et al. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood. 2007 Mar 1;109(5):2112-20.|[2]Sako H, et al. Antitumor effect of the tyrosine kinase inhibitor Nilotinib on gastrointestinal stromal tumor (GIST) and Imatinib-resistant GIST cells. PLoS One. 2014 Sep 15;9(9):e107613.|[3]Dervis Hakim G, et al. Mucosal healing effect of nilotinib in indomethacin-induced enterocolitis: A rat model. World J Gastroenterol. 2015 Nov 28;21(44):12576-85.|[4]Fujita KI, et al. Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites. J Pharm Sci. 2017 Sep;106(9):2632-2641.|[5]Meirson T, et al. Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors. Oncotarget. 2018 Apr 24;9(31):22158-22183.ACS Chem Biol. 2016 Apr 15;11(4):992-1000.|Biomaterials. 16 September 2022.|Biomed Chromatogr. 2019 Dec;33(12):e4674.|Biomolecules. 2022 Jun 11;12(6):819.|bioRxiv. 2024 May 8:2024.05.07.592424.|Br J Cancer. 2021 Nov 24.|Breast Cancer Res. 2023 May 5;25(1):51.|Cancer Biol Ther. 2019;20(6):877-885.|Cancer Lett. 2024 Aug 1:217150.|Cancer Med. 2016 Nov;5(11):3223-3234.|Cancer Res. 2024 Oct 22.|Cell Death Dis. 2021 Sep 25;12(10):875.|Cell Mol Immunol. 2024 Aug;21(8):856-872.|Cell Syst. 2018 Apr 25;6(4):424-443.e7.|Diseases. 2023 Oct 23;11(4):147.|Eur J Pharmacol. 2021 Feb 10;173944.|Glia. 2022 Feb 13.|Harvard Medical School LINCS LIBRARY|Int J Mass Spectrom. 442 (2019) 44-50.|J Pharm Sci. 2017 Sep;106(9):2632-2641.|Leuk Lymphoma. 2015;56(8):2416-23. |Oncotarget. 2018 Apr 24;9(31):22158-22183. |Patent. US20190084960A1|Patent. US20210299273A1.|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.|Stem Cell Reports. 2019 May 14;12(5):996-1006. |Target Oncol. 2020 Oct;15(5):659-671.|Technical University of Munich. 24.01.2018.|Toxicol Lett. 2022 Jun 6;S0378-4274(22)00117-5.|Toxicology. 2024 May 15:505:153830.|Xenobiotica. 2018 Oct;48(10):1059-1071. |bioRxiv. January 25, 2022.|Cell Rep Methods. 2023 Oct 23;3(10):100599.|Drug Metab Pharmacokinet. 2020 Feb;35(1):102-110.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Launched

• CAS Number:

  641571-10-0